Cryoablation Technology's Role in Breast Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Guideline Update: The American Society of Breast Surgeons (ASBrS) is updating its treatment guidelines for benign and malignant breast tumors to include cryoablation, marking a significant step towards widespread adoption of this technology in breast cancer treatment in the U.S.
- Clinical Evidence Support: The ICE3 trial demonstrated that only 3.1% of patients treated with cryoablation and endocrine therapy experienced local recurrence within five years, showcasing the method's efficacy and safety, potentially establishing it as a new standard of care.
- Significant Market Potential: The ProSense® system targets approximately 200,000 breast cancer patients annually, particularly low-risk patients aged 70 and above, and is expected to accelerate commercial adoption and expand reimbursement coverage, enhancing treatment options for patients.
- Accelerated Industry Recognition: ASBrS will be the first medical society to include cryoablation in its guidelines just three months after FDA approval, likely prompting more surgeons to recommend this minimally invasive treatment, thereby improving patient outcomes.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.630
Low
3.00
Averages
3.00
High
3.00
Current: 0.630
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








